Quest Diagnostics launches new FDA-cleared blood test for Alzheimer's pathology assessment
The company adds Roche pTau217 to its AD-Detect portfolio and introduces a multi-biomarker lab-developed test with low indeterminate rates.
See the latest news and media coverage for Quest. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical diagnostic testing and laboratory services provider
questdiagnostics.comLast updated
In short: Quest achieved strong 2026 financial growth, raised its annual outlook, and expanded its diagnostics portfolio through new partnerships.
The company adds Roche pTau217 to its AD-Detect portfolio and introduces a multi-biomarker lab-developed test with low indeterminate rates.
Second quarter diluted EPS rose to $2.84, and adjusted EPS to $3.12. Revenue reached $3.04 billion, with organic growth of 10%.
Hair test positivity for marijuana rose 58.9% over five years, while overall urine positivity stayed above 4%.
A pilot program with American Oncology Network provides access to Haystack MRD and comprehensive genomic profiling.
While Quest Diagnostics has outpaced the broader market over the past year, Wall Street analysts mai...
Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification...
Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powerin...
DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project...
Track Quest and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Quest and other trending companies.